L'HMGB2 derivato dal tumore induce la polarizzazione dei macrofagi M2 via degradazione NLRP3 mediata da TRIM65 per promuovere la progressione del DLBCL.

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. Although standard immunochemotherapy is available, 30%-40% of patients develop refractory or relapsed disease, underscoring the need to elucidate the underlying mechanisms of therapy resistance. High mobility group box 2 (HMGB2) is overexpressed in DLBCL; however, its role in the pathogenesis of DLBCL and in mediating therapy resistance remains unclear. METHODS: HMGB2 expression and prognostic value in DLBCL were analyzed using public databases, validated by quantitative reverse transcription-PCR and western blot analysis. In vivo and in vitro HMGB2 knockdown models were constructed to ex